Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications. Post navigationPreviousPrevious post:Dr. Neil Buckholtz of the NIA discusses ADNI in a summary of the recent presentations at the AAIC in Copenhagen and other Alzheimer’s research news.NextNext post:Exercise may help to keep the brain active in people with an increased risk of developing Alzheimer’s disease, according to a new study conducted by the Cleveland Clinic.